A novel assay using a pharmacologically relevant piperaquine dosetime exposure was designed. Chloroquine versus dihydroartemisininpiperaquine with standard highdose primaquine given either for 7 days or 14 days in plasmodium vivax malaria cindy s chu shoklo malaria research unit, mahidoloxford tropical medicine research unit, faculty of tropical medicine, mahidol university, mae sot, thailand. Optimal dosing of dihydroartemisininpiperaquine for seasonal. Ibasunate dihydroartemisinin and piperaquine phosphate. Dihydroartemisinin piperaquine and artemetherlumefantrine probably have similar side effects moderate quality evidence. Historically, antimalarial drugs have been used at a population level in malariaendemic areas with the objective of decreasing the burden, impact, and transmissibility of malaria. An openlabel, randomised study of dihydroartemisininpiperaquine versus artesunate mefloquine for. Dihydroartemisinin piperaquine holds promise as an option. Food and drink were given before drug administration. Our results show that 1 k mutation has become dominant and that piperaquine resistance is present in vietnam. Efficacy of dihydroartemisininpiperaquine for the treatment of uncomplicated plasmodium falciparum and plasmodium vivax in cambodia, 20082010. Mar 10, 2016 dihydroartemisininpiperaquine is an especially attractive combination therapy, given its prolonged posttreatment prophylactic effect.
Studies have shown that eurartesims long halflife affords patients a useful period of protection from new malaria infections. In southeast asia, where resistance has emerged towards both artemisinin and piperaquine, the combination is being trialed with a third drug, namely mefloquine. Formulation of dihydroartemisininpiperaquine dhp generic tablet as antimalarials drug article pdf available september 2016 with 631 reads how we measure reads. A list of us medications equivalent to dihydroartemisinin is available on the website. Patient information and corresponding data from in vitro piperaquine survival assays performed on 32 cultureadapted p. Dihydroartemisininpiperaquine dhp is the first line therapy recommended for. A randomized trial to guide policy in uganda plos one, jun 2008 adoke yeka, grant dorsey, moses r.
The dramatic decline in efficacy of dihydroartemisininpiperaquine compared with what was observed in a study at the same location in 2010 was strongly associated with a new triple mutation including the kelch cys580tyr substitution. Dihydroartemisininpiperaquine treatment failure in. Research article open access plasmodium falciparum dihydroartemisininpiperaquine failures in cambodia are associated with mutant k parasites presenting high survival rates in novel piperaquine in vitro assays. Piperaquine is an antimalarial agent first synthesized in the 1960s and used throughout china. Dihydroartemisinin piperaquine as above plus primaquine 0. Plasmodium falciparum dihydroartemisininpiperaquine.
Dihydroartemisininpiperaquine versus chloroquine to treat. Stability of dihydroartemisininpiperaquine tablet halves during prolonged storage under tropical conditions, the american journal of tropical. It has come back into use in combination with the artemisinin derivative db11638 as part of the combination product eurartesim. Research article open access plasmodium falciparum. Treatment failures in cases with pfpm2 amplificationpositive parasites and adequate piperaquine exposure support the presence of piperaquine resistance in vietnam. An indonesian observational study detected a higher rate of abortion after first trimester exposure to dihydroartemisininpiperaquine poespoprodjo 2014. Available in vitro piperaquine susceptibility assays do not correlate with treatment outcome. In studies of people living in asia, dihydroartemisinin piperaquine is as effective as artesunate plus mefloquine at treating malaria moderate quality evidence. The combination dihydroartemisinin piperaquine is an effective antimalarial that is used widely around the world. Jan, 2016 g6pd normal participants will be treated with dihydroartemisininpiperaquine eurartesim. Dec 15, 2012 artemisininbased combination regimens are recommended by who for the treatment of uncomplicated plasmodium falciparum malaria. However, dihydroartemisininpiperaquine cures slightly more.
Sigma tau administered as 3 tablets 40mg ppq, 320mg dha in a once daily regimen for three days in combination with a single dose of 0. Nov 16, 2016 historically, antimalarial drugs have been used at a population level in malariaendemic areas with the objective of decreasing the burden, impact, and transmissibility of malaria. Ex vivo responses to dihydroartemisinin dha and in vitro reponses to piperaquine were assessed in 914 p. A randomized trial to monitor the efficacy and effectiveness by qtnasba of artemetherlumefantrine versus dihydroartemisininpiperaquine for treatment and transmission control of uncomplicated plasmodium falciparum malaria in western kenya. The effect of mgkg dose of piperaquinelumefantrine, act. Dihydroartemisinin is used to treat malaria, generally as a combination drug with piperaquine. Delayed parasite clearance was first detected after treatment with dihydroartemisinin piperaquine in bu dang district of binh phuoc province in 2009. Application of dihydroartemisinin plus piperaquine for inclusion in the model list of essential medicines pdf, 285kb. Use of the information, documents and data from the echa website is subject to the terms and conditions of this legal notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the echa website may be reproduced, distributed andor used, totally or in part, for noncommercial purposes provided that echa is. The combination dihydroartemisininpiperaquine is an effective antimalarial that is used widely around the world. Plasmodium falciparum dihydroartemisininpiperaquine failures. Dihydroartemisininpiperaquine failure associated with a. Treatment failure of dihydroartemisininpiperaquine for.
Frequently asked questions about eurartesim medicines for. Stability of dihydroartemisininpiperaquine tablet halves. Dr jenny hill, liverpool school of tropical medicine. Mar 29, 2018 dihydroartemisinin 40 mg and piperaquine phosphate 320 mg capsules. Dihydroartemisininpiperaquine dhappq is the artemisinin combination therapy that was recently introduced for the treatment of plasmodium falciparum uncomplicated malaria, but emerging resistance in southeast asia is threatening its use. Dihydroartemisinin is a medicine available in a number of countries worldwide. For piperaquine, only in the case of a crossover study, the analytical. Strict regulation and monitoring of antimalarial use, along. Stability of dihydroartemisinin piperaquine tablet halves during prolonged storage under tropical conditions eva maria hodel 1 2 3 harparkash kaur 0 2 dianne j. Dihydroartemisininpiperaquine, one of the last remaining medications effective against multidrugresistant plasmodium falciparum, was adopted as the firstline antimalarial agent in cambodia in. Act to combat malaria receives marketing authorization. Researchers tested the efficacy of threedose and monthlydose dihydroartemisininpiperaquine and compared the results with sulfadoxinepyrimethamine.
Artemetherlumefantrine versus dihydroartemisininpiperaquine. As a result of increasing resistance to sulfadoxinepyrimethamine, new treatments are necessary to prevent malaria in pregnant women in africa. Combined ex vivo psa and k genotyping provides a convenient monitor for both artemisinin and piperaquine resistance where dihydroartemisinin piperaquine is used. Dihydroartemisinin is especially useful for the treatment of cases resistant to chloroquine. A fixed oral combination of the bisquinolone piperaquine and dihydroartemisinin dhp is a new and promising artemisininbased combination therapy. Support letter from medicines for malaria venture pdf, 317kb. The world health organization recommended the use of artemisininbased combination therapies acts for treatment of uncomplicated falciparum malaria a decade ago in response to problems of drug resistance. Leang r, barrette a, mey bouth d, menard d, abdur r, duong s, ringwald p. Select up to three search categories and corresponding keywords using the fields to the right. Dihydroartemisininpiperaquine and azithromycinbased combinations are showing great promise as potential candidates for iptp but pharmacokinetic data suggest that dose modification may be. Eurartesim dihydroartemisininpiperaquine medicines for. Dihydroartemisininpiperaquine failure in cambodia nejm. This report describes a case of dhappq treatment failure in uncomplicated malaria occurring in an immigrant living in italy, after a travel to. Artemisinin resistant plasmodium falciparum has emerged in the countries of the greater mekong subregion posing a serious threat to global malaria elimination efforts.
Does the use of dihydroartemisininpiperaquine in treating patients with uncomplicated falciparum malaria reduce the risk for recurrent new falciparum infection. A change in the malaria treatment policy for vietnam is in process. The only brand of dihydroartemisininpiperaquine that has been. Piperaquine phosphate salt used in dosage form sae.
Does the use of dihydroartemisininpiperaquine in treating. A high number of treatment failures 1440 was found, and piperaquine resistance in vietnam was confirmed. Dihydroartemisininpiperaquine for the prevention of malaria in. Although dihydroartemisininpiperaquine has previously been effective in africa and southeast asia, 1,4 the high failure rate, as compared with 2010, constitutes the second report of poor. Jan 28, 2019 scientific reports 2019 reduced exposure to piperaquine, compared to adults, in young children receiving dihydroartemisinin. Although dihydroartemisinin piperaquine dp treatment is a welltolerated, effective therapy for uncomplicated malarial infections, this drug combination is known to interfere with cardiac repolarization by prolonging qt intervals on electrocardiograms. Patients in the chloroquine group who completed treatment received a median total dose of 25. Impact of dihydroartemisininpiperaquine plus primaquine. For patients whether local or travellers treated in countries in which malaria is endemic, the slow clearance of piperaquine prevents new infections for 4060 days. Dihydroartemisinin an overview sciencedirect topics.
Dihydroartemisininpiperaquine holds promise as an option for malaria prevention in pregnancy 10. In annual studies conducted in three malaria endemic provinces in the south of vietnam binh phuoc, ninh thuan and gia lai between 2011 and. Dihydroartemisinin piperaquine dihydroartemisinin 7 mgkg and piperaquine 55 mgkg. Impact of dihydroartemisininpiperaquine plus primaquine on malaria transmission in lampung province, sumatra the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. One such combination comprises the artemisinin derivative dihydroartemisinin and the bisquinolone piperaquine.
Dihydroartemisininpiperaquine dhappq oral essential drugs. Chloroquine versus dihydroartemisininpiperaquine with. Jan 29, 2019 increasing the dihydroartemisinin piperaquine dosage and extending the dose schedule to four monthly doses result in a predicted relative reduction in malaria incidence of up to 58% during the. Efficacy of dihydroartemisinin piperaquine for the treatment of uncomplicated plasmodium falciparum and plasmodium vivax in cambodia, 20082010. The dihydroartemisinin would, for certain individuals bring effects of greater or lesser severity for example, a reversible reduction in reticulocyte counts. Table 4 does the use of dihydroartemisininpiperaquine in. The safety and efficacy of a novel combination of dihydroartemisinin dha and piperaquine, artekin holleykin pharmaceuticals, were assessed in 106 patients 76 children and 30 adults with uncomplicated falciparum malaria from 2 remote areas in cambodia. Wellcome trust southeast asian tropical medicine research programmes pdf, 177kb. Bassat q, mulenga m, tinto h, piola p, borrmann s, et al. Welcome to cdc stacks rethinking dosing regimen selection. Embargoed until noon, wednesday 30 november 2011 press release eurartesim dihydroartemisinin piperaquine act to combat malaria receives marketing authorization from ema a fixeddose combination therapy to combat malaria, eurartesim, dihydroartemisinin piperaquine the product of italian research conducted by sigmatau and mmv, approved by the european medicines. Antimalarial drug containing the combination of dihydroartemisinin 80mg and piperaquine phosphate 640mg per 80ml was purchased from a local pharmaceutical store in nigeria.
The dramatic decline in efficacy of dihydroartemisinin piperaquine compared with what was observed in a study at the same location in 2010 was strongly associated with a new triple mutation including the kelch cys580tyr substitution. Artemisininbased combination regimens are recommended by who for the treatment of uncomplicated plasmodium falciparum malaria. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a pdf plugin installed and enabled in your browser. Effects of dihydroartemisininpiperaquine phosphate and. Rapid decline in the susceptibility of plasmodium falciparum. Dihydroartemisininpiperaquine tetraphosphate 20mg160mg tablets.
Coformulated tablets of dihydroartemisinin dhapiperaquine ppq, in blister pack, for a complete treatment for one individual there are 5 different blister packs. Does the use of dihydroartemisinin piperaquine in treating patients with uncomplicated falciparum malaria reduce the risk for recurrent new falciparum infection more than artemetherlumefantrine. Dihydroartemisininpiperaquine for the prevention of. Dihydroartemisininpiperaquine dhappq oral essential. Formulation of dihydroartemisininpiperaquine dhp generic tablet as antimalarials drug. It is thought that the risk of cardiotoxicity may be. Table 4 does the use of dihydroartemisininpiperaquine.
The relationship of artemisinin resistance to treatment failure has been unclear. Malaria contributes significantly to the global disease burden. Evaluation of the safety of primaquine in combination with. Terlouw 1 2 3 0 london school of hygiene and tropical medicine, london, united kingdom 1 malawiliverpoolwellcome trust clinical research programme, blantyre, malawi 2 tropical medicine, liverpool, united. Guilin pharmaceutical company, china over 3 days and primaquine 1 mg basekgday for 7 days. Dihydroartemisininpiperaquine has been shown to be effective for the treatment of malaria in pregnant and nonpregnant populations 29,30 and for the prevention of malaria in children and. Dihydroartemisinin piperaquine and azithromycinbased combinations are showing great promise as potential candidates for iptp but pharmacokinetic data suggest that dose modification may be. Three of the regimes had excellent and similar efficacy in treating the malaria attack, but of those, treatment with combination dihydroartemisininpiperaquine the combination most recent recommended by the who resulted in significantly fewer recurrent infections. The declining efficacy of dihydroartemisininpiperaquine against plasmodium falciparum in cambodia, along with increasing numbers of recrudescent cases, suggests resistance to both artemisinin and piperaquine.
Artemetherlumefantrine versus dihydroartemisinin piperaquine for treating uncomplicated malaria. Pdf formulation of dihydroartemisininpiperaquine dhp. Dihydroartemisinin piperaquine and artemetherlumefantrine for treating uncomplicated malaria in african children. Article pdf available september 2016 with 650 reads. Psa adequately captures the piperaquine resistancerecrudescence phenotype, a mainstay to identify molecular markers and evaluate efficacy of alternative drugs. The parent drug is considered to best reflect the biopharmaceutical quality of the proposed product. Increasing the dihydroartemisininpiperaquine dosage and extending the dose schedule to four monthly doses result in a predicted relative reduction in malaria incidence of up to 58% during the. Dihydroartemisinin what does dihydroartemisinin stand. Impact of dihydroartemisininpiperaquine plus primaquine on. A change in the malaria treatment policy to treat with artesunate. The world health organization who recommends artemisinin. Reappraising the cardiosafety of dihydroartemisininpiperaquine.
Dihydroartemisininpiperaquine for the prevention of malaria. Dihydroartemisinin piperaquine kills the parasites quickly, producing a fast resolution of clinical signs and symptoms. Treated with fixed doses of 40 mg dihydroartemisinin and 320 mg piperaquine based on weight for 3 days d0, d1 and d2 with max dose of 1 x 3 tablets for patients weighing. Hmdb is offered to the public as a freely available resource. Efficacy and safety of dihydroartemisininpiperaquine.
Artemisininbased combination therapy depressed mitosis and induced chromosome aberration in onion root cells. Optimal dosing of dihydroartemisininpiperaquine for. Kamya, ambrose talisuna, myers lugemwa, john bosco rwakimari, sarah g. A novel assay using a pharmacologically relevant piperaquine dosetime exposure. Eurartesim has proved effective in the treatment of uncomplicated plasmodium falciparum malaria. Dihydroartemisininpiperaquine is an especially attractive combination therapy, given its prolonged posttreatment prophylactic effect. We compared the effects of dihydroartemisininpiperaquine phosphate dhapqp and artemetherlumefantrine al on qt interval duration in healthy volunteers. Dec 22, 2015 the declining efficacy of dihydroartemisinin piperaquine against plasmodium falciparum in cambodia, along with increasing numbers of recrudescent cases, suggests resistance to both artemisinin and piperaquine.
33 1173 523 745 470 522 1233 510 458 929 1558 699 1426 1129 643 1507 1218 303 721 407 232 320 985 974 740 1414 538 1507 15 691 680 478 1062 202 1172 1229